Trillium Therapeutics Inc logo

TRIL - Trillium Therapeutics Inc Share Price

C$10.84 -0.2  -1.9%

Last Trade - 8:25pm

Sector
Healthcare
Size
Mid Cap
Market Cap £527.9m
Enterprise Value £442.1m
Revenue £19.0k
Position in Universe 254th / 2675
Bullish
Bearish
Unlock TRIL Revenue
Momentum
Relative Strength (%)
1m +2.13%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -15.5%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 0.12
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the three months ended 31 March 2020, Trillium Therapeutics Inc revenues was not reported. Net loss increased from $8M to $70.1M. Higher net loss reflects Revaluation of warrant liability, net decrease from $479K (income) to $55.2M (expense), Other SGA increase from $374K (income) to $9.3M (expense), Salaries, fees and short-term benefits increase of 76% to $859K (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for TRIL
Graphical History

Revenue

TRIL Revenue Unlock TRIL Revenue

Net Income

TRIL Net Income Unlock TRIL Revenue

Normalised EPS

TRIL Normalised EPS Unlock TRIL Revenue

PE Ratio Range

TRIL PE Ratio Range Unlock TRIL Revenue

Dividend Yield Range

TRIL Dividend Yield Range Unlock TRIL Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
TRIL EPS Forecasts Unlock TRIL Revenue
Profile Summary

Trillium Therapeutics Inc is a Canada-based clinical stage immuno-oncology company developing therapies for the treatment of cancer. The Company leads program, TTI-621, which is a SIRPaFc fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin (IgG1). It is designed to act as a soluble decoy receptor, preventing CD47 from delivering its inhibitory (''do not eat'') signal. Neutralization of the inhibitory CD47 signal enables the activation of macrophage anti-tumor effects by pro-phagocytic (''eat'') signals. A Phase one clinical trial (NCT02663518) evaluating intravenous dosing of SIRPaFc in patients with cancer is ongoing, and a second Phase one trial evaluating direct intratumoral injections is underway in solid tumors and mycosis fungoides (NCT02890368). TTI-622 is an IgG4 SIRPaFc protein, which is primarily being developed for combination therapy. An IND filing is targeted for 2H/17.

Directors
Last Annual December 31st, 2019
Last Interim March 31st, 2020
Incorporated March 31, 2004
Public Since January 11, 2005
No. of Shareholders: n/a
No. of Employees: 29
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange Toronto Stock Exchange
Shares in Issue 83,436,508
Free Float (0.0%)
Eligible for
ISAs
SIPPs
TRIL Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for TRIL
Upcoming Events for TRIL
Frequently Asked Questions for Trillium Therapeutics Inc
What is the Trillium Therapeutics Inc share price?

As of 8:25pm, shares in Trillium Therapeutics Inc are trading at C$10.84, giving the company a market capitalisation of £527.9m. This share price information is delayed by 15 minutes.

How has the Trillium Therapeutics Inc share price performed this year?

Shares in Trillium Therapeutics Inc are currently trading at C$10.84 and the price has moved by 2.36k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Trillium Therapeutics Inc price has moved by 2.32k% over the past year.

What are the analyst and broker recommendations for Trillium Therapeutics Inc?

Of the analysts with advisory recommendations for Trillium Therapeutics Inc, there are there are currently 0 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Trillium Therapeutics Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Trillium Therapeutics Inc next release its financial results?

Trillium Therapeutics Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-03-31
What is the Trillium Therapeutics Inc dividend yield?

Trillium Therapeutics Inc does not currently pay a dividend.

Does Trillium Therapeutics Inc pay a dividend?

Trillium Therapeutics Inc does not currently pay a dividend.

When does Trillium Therapeutics Inc next pay dividends?

Trillium Therapeutics Inc does not currently pay a dividend.

How do I buy Trillium Therapeutics Inc shares?

To buy shares in Trillium Therapeutics Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Trillium Therapeutics Inc?

Shares in Trillium Therapeutics Inc are currently trading at C$10.84, giving the company a market capitalisation of £527.9m.

Where are Trillium Therapeutics Inc shares listed? Where are Trillium Therapeutics Inc shares listed?

Here are the trading details for Trillium Therapeutics Inc:

Country of listing: Canada
Exchange: TOR
Ticker Symbol: TRIL
What kind of share is Trillium Therapeutics Inc?

Based on an overall assessment of its quality, value and momentum, Trillium Therapeutics Inc is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Trillium Therapeutics Inc share price forecast 2020?

Shares in Trillium Therapeutics Inc are currently priced at C$10.84. At that level they are trading at 3.98% premium to the analyst consensus target price of 0.00.

Analysts covering Trillium Therapeutics Inc currently have a consensus Earnings Per Share (EPS) forecast of -0.8861989091 for the next financial year.

How can I tell whether the Trillium Therapeutics Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Trillium Therapeutics Inc. Over the past six months, the relative strength of its shares against the market has been 0.131k%. At the current price of C$10.84, shares in Trillium Therapeutics Inc are trading at 92.82% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Trillium Therapeutics Inc PE Ratio?

We were not able to find PE ratio data for Trillium Therapeutics Inc.

Who are the key directors of Trillium Therapeutics Inc?

Trillium Therapeutics Inc's management team is headed by:

James Parsons - CFO
Calvin Stiller - CHM
Michael Moore - IND
Robert Uger - CSO
Scott Duncan - OTH
Luke Beshar - IND
Henry Friesen - IND
Robert Kirkman - CHM
Thomas Reynolds - IND
Penka Petrova - OTH
Malik Slassi - SVP
Yaping Shou - OTH
Jan Skvarka - PRE
Paul Walker - DRC
Ali Behbahani - DRC
Who are the major shareholders of Trillium Therapeutics Inc?

Here are the top five shareholders of Trillium Therapeutics Inc based on the size of their shareholding:

VR Adviser, LLC Venture Capital
Percentage owned: 8.14% (6.79m shares)
RA Capital Management, LP Hedge Fund
Percentage owned: 7.62% (6.36m shares)
New Enterprise Associates (NEA) Venture Capital
Percentage owned: 6.88% (5.74m shares)
Avoro Capital Advisors LLC Investment Advisor/Hedge Fund
Percentage owned: 5.93% (4.95m shares)
Boxer Capital, L.L.C. Hedge Fund
Percentage owned: 4.88% (4.08m shares)
Similar to TRIL
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.